Compare FirstEnergy Corp. (FE) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FirstEnergy Corp. vs Travere Therapeutics Inc. Common Stock — how do they compare? FirstEnergy Corp. trades at $45.72 (market cap $26.16B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: FirstEnergy Corp. is far larger — about 5.4× Travere Therapeutics Inc. Common Stock's market cap, and FirstEnergy Corp. pays a 4.11% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold FirstEnergy Corp. for 72 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| FE | TVTX | |
|---|---|---|
Market Cap | $26.16B | $4.88B |
Volume | 4,932,658 | 1,668,577 |
Sector | Utilities | Health |
52-Week High | $51.91 | $67.52 |
52-Week Low | $43.04 | $26.79 |
Typical Hold Time | 72 Days | 0 Days |
Enterprise Value | $55.08B | $5.01B |
Dividend Yield | 4.11% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FirstEnergy (FE) trades at $45.41, up 0.11% with a bullish technical signal. The stock shows mixed earnings performance with Q1 2026 beating expectations but Q4 2025 and Q2 2026 missing. Revenue grew to $15.09B in 2025 with a 6.86% net margin. Analyst consensus is Moderate Buy with a $51.00 price target, representing 12.3% upside. Recent developments include the Energize365 investment plan and consistent dividend payments.
FirstEnergy presents a stable utility investment with moderate growth potential through infrastructure investments. Key opportunities include the $36B Energize365 plan and rising data-center demand. Risks include high debt levels ($24.03B total debt), interest rate sensitivity, and regulatory challenges. The stock offers income through dividends but faces execution risks on capital projects.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About FirstEnergy Corp.
FirstEnergy is one of the largest investor-owned utilities in the United States with 10 regulated distribution companies across six mid-Atlantic and Midwestern states. FirstEnergy also owns and operates one of the nation's largest electric transmission systems with 24,000 miles of lines.
Read more on FE →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
